Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 6Biliary Tract Neoplasms 5Sarcoma 3Rectal Neoplasms 3Colonic Neoplasms 3Advanced or Metastatic Solid Tumors 3Solid Tumors 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Rare Tumour 1Prostatic Neoplasms 1Piebaldism 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Multiple Primary 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1

Interventions

Paclitaxel 3Carboplatin 3tremelimumab 1pembrolizumab 1necitumumab 1envafolimab 1durvalumab 1anlotinib 1Nivolumab 1Gemcitabine 1Endostatins 1Drug Therapy 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Squamous Non-small Cell Lung Cancer × envafolimab × Clear all
NCT05243355 2022-02-17

Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC

Qilu Hospital of Shandong University

Phase 2 Unknown
46 enrolled
Thoracic

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡